Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR

According to new report from BCC Research, the global market RNA interference (RNAi) drug delivery technologies is expected to grow to nearly $38.8 billion by 2018, with a five-year compound annual growth rate (CAGR) of 27.2%. The aptamer delivery category, the fastest moving segment of the market, is moving at a phenomenal 58.2% CAGR.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
SAMPLE FIGURE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES, 2013-2018 ($ MILLIONS)

SAMPLE FIGURE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES, 2013-2018 ($ MILLIONS)

Global Market for RNAI Drug Delivery Technologies to Reach $38.8 Billion in 2018

Wellesley, Mass. (PRWEB) August 01, 2014

BCC Research (http://www.bccresearch.com) reveals in its new report, RNAi DRUG DELIVERY: TECHNOLOGIES AND GLOBAL MARKETS, that the global market RNA interference (RNAi) drug delivery technologies is expected to grow to nearly $38.8 billion by 2018, with a five-year compound annual growth rate (CAGR) of 27.2%. The aptamer delivery category, the fastest moving segment of the market, is moving at a phenomenal 58.2% CAGR.

The field of RNAi therapeutics has shown tremendous growth and has moved toward clinical trials. Nonetheless, the development of RNAi therapeutics is dependent on safe, effective, and clinically suitable delivery carriers. The nanoparticle delivery category is the largest segment of the overall market and is expected to grow to $33.4 billion by 2018, registering a CAGR of 25%.

However, the aptamer delivery category, which was valued at just $218 million in 2013, is expected to jump to nearly $2.2 billion in 2018. Aptamers offer several advantages compared to protein or small-molecule drugs, most notably their ease of production, low risk of inducing an immune reaction in humans, and amenability to chemical modifications that enhance their drug-like properties, including improved stability and residence time in the bloodstream.

“There has been immense progress in the field of nanotechnology for drug delivery, and efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems,” says BCC Research biotechnology analyst Usha Nagavarapu. “A carefully engineered, multifunctional nanocarrier with targeting capabilities is needed to address the delivery challenges.”

The RNAi technologies market has application in the areas of therapeutics, research, and development (functional genomics; metabolism), drug discovery, and agriculture. The therapeutics application market is focused on oncology, neurology, cardiology, ophthalmology, and metabolic disorders, and is expected to grow in the next few years.

RNAi DRUG DELIVERY: TECHNOLOGIES AND GLOBAL MARKETS provides an overview of the global market for RNAi drug delivery technologies. It includes analyses of global market trends, with data from 2010, 2012, and 2013, estimates for 2018, projections of CAGRs through 2018, and profiles of companies important in the industry.

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven(dot)cumming(at)bccresearch(dot)com.

About BCC Research:

BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years, we have helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key competitors. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Our clients include the top companies in industries around the world, as well as universities, business schools, start-ups, consulting firms, and investment companies. BCC Research is a unit of Eli Research LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or email information(at)bccresearch(dot)com.

Note:
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49-2 Walnut Park, Wellesley, MA 02481, Telephone: (+1) 781-489-7301; Email: editor(at)bccresearch(dot)com as the source and publisher. Thank you.


Contact